

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number		Complete if Known 10/517251
Filing Date		June 6, 2003
First Named Inventor		Phillip Mark Hogarth
Art Unit		1632
Examiner Name		Lieto
Attorney Docket Number		4602AL-1

Sheet 1 of 1

U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No.†	Document Number Number-kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.†	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code*	Number* Kind Code* (if known)				
WOL		PCT	- WO 96/08512	03/21/1996	Austin Research Institute Cancer and Antiinflammatory Syndicate No.1		
WOL		PCT	- WO 95/28959	11/02/1995	Sloan-Kettering Institute for Cancer Research		
			-				
			-				
			-				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No.†	
WOL		"The Role of Human Fc Receptor FcγRIIA in the Immune Clearance of Platelets: A Transgenic Mouse Model", McKenzie et al., The Journal Immunology, pp. 4311-4318 (1999) Vol. 162
WOL		"Functional Consequences of the Interaction Between T-cell Antigen Receptors and FcγRs on T Cells", Kwack et al., Immunology Letters, 44 (1995) pp. 139-143, Elsevier Science B.V.

Examiner Signature		Date Considered	4/3/06
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.